Scarica l'app Stockscreener
105.43
0.20%
-0.21
Dopo l'orario di chiusura:
105.43
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NUVL Giù?
Forum
Previsione
Precedente Chiudi:
$105.64
Aprire:
$103.84
Volume 24 ore:
991.50K
Relative Volume:
1.79
Capitalizzazione di mercato:
$8.29B
Reddito:
-
Utile/perdita netta:
$-425.38M
Rapporto P/E:
-18.02
EPS:
-5.8504
Flusso di cassa netto:
$-275.21M
1 W Prestazione:
+7.52%
1M Prestazione:
+4.09%
6M Prestazione:
+25.72%
1 anno Prestazione:
+49.63%
Intervallo 1D:
$102.04
$106.46
Intervallo di 1 settimana:
$95.59
$106.90
Portata 52W:
$55.53
$113.02
Nuvalent Inc Stock (NUVL) Company Profile
Nome
Nuvalent Inc
Settore
Industria
Telefono
508-446-2272
Indirizzo
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
105.43 | 8.29B | 0 | -425.38M | -275.21M | -5.8504 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-12 | Iniziato | Canaccord Genuity | Buy |
| 2025-10-16 | Ripresa | Stifel | Buy |
| 2025-10-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-09-03 | Iniziato | Raymond James | Outperform |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-03-14 | Aggiornamento | UBS | Neutral → Buy |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-24 | Iniziato | UBS | Neutral |
| 2024-08-29 | Iniziato | Barclays | Overweight |
| 2024-04-17 | Iniziato | Jefferies | Buy |
| 2024-04-01 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Ripresa | Guggenheim | Buy |
| 2024-02-23 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-27 | Iniziato | Stifel | Buy |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-24 | Iniziato | Guggenheim | Buy |
| 2023-01-18 | Iniziato | Wedbush | Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
Mostra tutto
Nuvalent Inc Borsa (NUVL) Ultime notizie
NUVL PE Ratio & Valuation, Is NUVL Overvalued - intellectia.ai
Nuvalent CFO Sells $1.2M in Shares - National Today
Nuvalent (NASDAQ:NUVL) CFO Alexandra Balcom Sells 11,430 Shares - MarketBeat
Nuvalent (NUVL) CFO sells 11,430 shares after option exercise under 10b5-1 plan - Stock Titan
[Form 4] Nuvalent, Inc. Insider Trading Activity - Stock Titan
Wells Fargo Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $116 - Moomoo
Nuvalent Insider Sold Shares Worth $537,943, According to a Recent SEC Filing - MarketScreener
Nuvalent (NUVL) CDO exercises options, sells 5,500 shares under 10b5-1 plan - Stock Titan
Goldman Sachs Maintains Nuvalent (NUVL) Buy Recommendation - MSN
Stifel Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $135 - moomoo.com
Price-Driven Insight from (NUVL) for Rule-Based Strategy - Stock Traders Daily
Stifel reiterates Buy rating on Nuvalent stock ahead of ROS1 launch - Investing.com Australia
22,000 Class A shares proposed sale — NUVL (NASDAQ: NUVL) - Stock Titan
Nuvalent Insider Sold Shares Worth $542,991, According to a Recent SEC Filing - MarketScreener
Nuvalent (NUVL) CLO exercises 5.5K options, sells 5.5K shares under 10b5-1 - Stock Titan
Nuvalent Initiated at Overweight by Wells Fargo - Moomoo
Wells Fargo initiates Nuvalent stock with overweight rating on drug potential By Investing.com - in.investing.com
Wells Fargo initiates Nuvalent stock with overweight rating on drug potential - Investing.com Canada
Nuvalent (NASDAQ:NUVL) Earns Overweight Rating from Analysts at Wells Fargo & Company - MarketBeat
Wells Fargo Initiates Nuvalent at Overweight With $116 Price Target - MarketScreener
Wells Fargo Initiates Nuvalent(NUVL.US) With Buy Rating, Announces Target Price $116 - Moomoo
Wells Fargo initiates coverage of Nuvalent (NUVL) with overweight recommendation - MSN
Upcoming AACR 2026 event announcement sees Nuvalent stock down 1.43% - Traders Union
Weekly Trades: Should I set a stop loss on Nuvalent IncQuarterly Trade Summary & Expert Curated Trade Setups - baoquankhu1.vn
Vanguard disaggregates holdings after realignment; Nuvalent (NUVL) ownership listed as 0 - Stock Titan
Nuvalent (NUVL) CFO sells 25,130 shares in Rule 10b5-1 trades - Stock Titan
S&P 500 Futures Drop in Premarket Trading; Nuvalent, Figure Tech Solns Lead - Barron's
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), TELA Bio (TELA) and Nuvalent (NUVL) - The Globe and Mail
NUVL (NASDAQ: NUVL) files Form 144 to sell Class A shares via J.P. Morgan - Stock Titan
ALK-Positive NSCLC Pipeline Gains Momentum as 6+ Pharma Companies Advance Next-Generation Therapies | DelveInsight - Barchart.com
Hudson Bay Capital Management LP Acquires Stake in Nuvalent, Inc. - National Today
Hudson Bay Capital Management LP Purchases New Stake in Nuvalent, Inc. $NUVL - MarketBeat
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally - AOL.com
Trend Report: Is Nuvalent Inc in a consolidation phase2026 Retail & Weekly Return Optimization Alerts - baoquankhu1.vn
Aug Catalysts: Is Nuvalent Inc in a consolidation phase2026 Price Swings & Daily Momentum Trading Reports - baoquankhu1.vn
Nuvalent (NUVL) officer Benjamin Lane details stock, options and RSUs in Form 3 - Stock Titan
(NUVL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
FDA Review of Zidesamtinib Data Might Change The Case For Investing In Nuvalent (NUVL) - Yahoo Finance
Cantor Fitzgerald L. P. Makes New $1.95 Million Investment in Nuvalent, Inc. $NUVL - MarketBeat
Does Nuvalent (NUVL) have the potential to rally 37.26% as Wall Street analysts expect? - MSN
Nuvalent to Present New Preclinical and Clinical Data for Zidesa - GuruFocus
Nuvalent to unveil new ROS1+ NSCLC clinical and preclinical data at AACR 2026 - Traders Union
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026 - StreetInsider
Vestal Point Sells Nuvalent Shares: Portfolio Impact and Company OutlookNews and Statistics - IndexBox
Nuvalent (NUVL) Gets a Buy from Canaccord Genuity - The Globe and Mail
Nuvalent, Inc. (NASDAQ:NUVL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally - The Motley Fool
Nuvalent's Chief Scientific Officer Sells Over 35,000 Shares - TradingView
Nuvalent (NUVL) CSO sells 35,104 shares after major option exercises - Stock Titan
Nuvalent, Inc. Holdings Raised by HighVista Strategies LLC - National Today
Nuvalent, Inc. $NUVL Holdings Raised by HighVista Strategies LLC - MarketBeat
Nuvalent Inc Azioni (NUVL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):